Literature DB >> 6631515

Calcium channel antagonist binding sites labeled by 3H-nimodipine in human brain.

S J Peroutka, G S Allen.   

Abstract

In vitro binding of 3H-nimodipine to human brain membranes is demonstrated in this study. This binding was specific and saturable, and had an apparent affinity constant (KD) of 0.27 nM. The maximal number of binding sites for 3H-nimodipine was 5.8 pmoles/gm wet weight of human frontal cortex. The binding was shown to be dependent on calcium, with half-maximal stimulation obtained at 3 X 10(-5) M CaCl2. Other 1,4-dihyropyridine calcium antagonists were shown to be competitive antagonists of 3H-nimodipine binding. In contrast, the calcium antagonists, verapamil and diltiazem, had complex interactions with 3H-nimodipine binding. These results represent the first identification of 3H-calcium antagonist binding sites in human brain, and they confirm that various calcium antagonist drugs may differ with respect to both their potency and their molecular site of action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631515     DOI: 10.3171/jns.1983.59.6.0933

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Nimodipine tested in a human model of cerebral ischaemia. Electroencephalographic and transcranial Doppler ultrasound investigations in normal subjects during standardized hyperventilation.

Authors:  V Kraaier; A C van Huffelen; G H Wieneke; J M Hesselink
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

3.  Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.

Authors:  D Tettenborn; L Porto; T Ryman; V Strugo; G Taquoi; R Battye
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

4.  Verapamil-induced changes in central conduction in patients with multiple sclerosis.

Authors:  R L Gilmore; E J Kasarskis; R G McAllister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

5.  A comparison of calcium antagonists and diazepam in reducing ethanol withdrawal tremors.

Authors:  G H Bone; E Majchrowicz; P R Martin; M Linnoila; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Dietary nimodipine delays the onset of methylmercury neurotoxicity in mice.

Authors:  Jordan M Bailey; Blake A Hutsell; M Christopher Newland
Journal:  Neurotoxicology       Date:  2013-04-09       Impact factor: 4.294

7.  The interaction of [3H]PY 108-068 and of [3H]PN 200-110 with calcium channel binding sites in rat brain.

Authors:  P Supavilai; M Karobath
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study.

Authors:  R W Seiler; P Grolimund; H R Zurbruegg
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

9.  Nimodipine promotes neurite outgrowth and protects against neurotoxicity in PC12 cells.

Authors:  Miduki Kusakabe; Yasushi Hasegawa
Journal:  Iran J Basic Med Sci       Date:  2021-01       Impact factor: 2.699

10.  Endovascular Treatment of Symptomatic Vasospasm after Aneurysmal Subarachnoid Hemorrhage: A Three-year Experience.

Authors:  Eun-Sung Park; Dae-Won Kim; Sung-Don Kang
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2017-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.